tiprankstipranks
Trending News
More News >

Immunic price target raised to $22 from $19 at Brookline

Brookline raised the firm’s price target on Immunic (IMUX) to $22 from $19 and keeps a Buy rating on the shares after the company announced data from its Phase 2 CALLIPER trial of nuclear receptor related 1 activator, vidofludimus calcium, in patients with progressive multiple sclerosis. The trial results, which met the firm’s expectations, “meaningfully reduce development risk,” the analyst tells investors.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1